Document Detail

Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock.
MedLine Citation:
PMID:  15373966     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: CD16+ CD14+ monocytes dramatically increase in number in patients with severe infection. Hemoperfusion with PMX-F (direct hemoperfusion with polymyxin B immobilized fibers) has been reported to be a safe and effective treatment for patients with septic shock, although the molecular mechanism that accounts for its effectiveness is still unclear. The purpose of this study was to quantify the number of CD16+ CD14+ monocytes in patients with an intra-abdominal infection and to evaluate the effects of PMX-F treatment on clinical parameters and leukocyte surface antigen expression in these patients. MATERIALS AND METHODS: Seventeen septic patients who had an intra-abdominal infection were enrolled in this study; 7 of these patients received PMX-F treatment. Peripheral blood samples were obtained immediately after admission, and were also collected from the above 7 patients before, during, and immediately after their PMX-F treatment. The expression of CD14, CD16, and Toll-like receptor (TLR)-4 on these patients' monocytes was evaluated using flow cytometry. In addition, lipopolysaccharide (LPS)-induced production of TNF-alpha and IL-1beta by these cells was measured by ELISA. RESULTS: Monocytic expression of CD16 and TLR-4 was significantly greater in septic patients than in healthy controls, and their proportion of CD16+ CD14+ monocytes was similarly elevated. LPS-induced production of TNF-alpha and IL-1beta by peripheral blood mononuclear cells (PBMCs) of septic patients was significantly reduced compared to controls. Furthermore, there was a reduction in the proportion of CD16+ CD14+ monocytes during PMX-F treatment, and in the expression of TLR-4 on monocytes after PMX-F treatment. CONCLUSIONS: These results showed that the number of peripheral blood CD16+ CD14+ monocytes and monocytic TLR-4 expression were markedly increased, and the production of pro-inflammatory cytokines in response to LPS significantly reduced in patients with sepsis. PMX-F treatment was found to be effective in reducing the number of CD16+ CD14+ monocytes and in decreasing the monocytic expression of TLR-4 in patients with septic shock.
Hironori Tsujimoto; Satoshi Ono; Shuichi Hiraki; Takashi Majima; Nobuaki Kawarabayashi; Hidekazu Sugasawa; Manabu Kinoshita; Hoshio Hiraide; Hidetaka Mochizuki
Related Documents :
8541556 - Impaired microbicidal capacity of mononuclear phagocytes from patients with type i gauc...
23991296 - C-reactive protein levels are raised in stable chronic obstructive pulmonary disease pa...
23933276 - Increased terc gene copy number and cells in senescence in primary sclerosing cholangit...
23335446 - Systemic mastocytosis with associated clonal hematological non-mast cell lineage diseas...
10831256 - A new method for the detection of incomplete lower esophageal sphincter relaxation in p...
25214236 - Autoimmune pancreatitis associated with pancreatic cyst: how can we manage it?
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of endotoxin research     Volume:  10     ISSN:  0968-0519     ISO Abbreviation:  J. Endotoxin Res.     Publication Date:  2004  
Date Detail:
Created Date:  2004-09-17     Completed Date:  2005-02-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9433350     Medline TA:  J Endotoxin Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  229-37     Citation Subset:  IM    
Department of Surgery I, National Defense Medical College Research Institute, Saitama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abdomen / microbiology
Anti-Bacterial Agents / administration & dosage,  therapeutic use*
Antigens, CD14 / analysis*
Cytokines / analysis
Enzyme-Linked Immunosorbent Assay
Flow Cytometry
Middle Aged
Monocytes / immunology*
Polymyxin B / administration & dosage,  therapeutic use*
Receptors, IgG / analysis*
Shock, Septic / immunology,  therapy*
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antigens, CD14; 0/Cytokines; 0/Receptors, IgG; 1404-26-8/Polymyxin B

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection of endotoxin in sera from children hospitalized for treatment of diarrhea in Bangladesh.
Next Document:  TLR4 Asp299Gly and Thr399Ile polymorphisms are very rare in the Chinese population.